Thematic Take

Powered by

Cyrus Mewawalla, Head of Thematic Intelligence, GlobalData

Foreword: ESG moves up the agenda

At GlobalData, we define a theme as any issue that keeps a business leader awake at night. Our thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. Companies that invest in the right themes become success stories. Those that miss the essential themes in their industry end up as failures.  

Environmental, social, and governance (ESG) is a theme that is becoming increasingly essential for all businesses to know and understand. Over the past five years, there has been a rapid increase in the number of companies conducting voluntary ESG reporting and promoting themselves, their products, and their services as sustainable.  

Now the market is being formalised. ESG reporting standards are being made mandatory in Europe, with the US likely to follow. A broader range of stakeholders scrutinise ESG claims, including regulators, shareholders, customers, and suppliers, and the consequences of exaggerating these claims go beyond short-term public relations embarrassment. 

In addition, there is a growing desire to hold companies accountable for ESG performance across their value chains. Many companies will be required to report scope 3 emissions, which include emissions generated by that company’s suppliers and customers.  

But it goes beyond emissions to the impact on communities, workers, and the local environment. The impact will not be confined to heavy industry and big polluters. All businesses must be aware of the growing significance of ESG and the risks and opportunities that come with it.

Go to article: Home | Nanoparticle drug delivery research gets a boostGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: NiproGo to article: In DepthGo to article: Covid-19 vaccine success bolsters nanoparticle drug delivery research Go to article: eConsent in clinical trials: What’s on the horizon?Go to article: Breathing easy: How digital inhalers are changing asthma treatmentGo to article: Primate models in pharma: What the future holds Go to article: A decade on, what’s next for CAR-T therapies?Go to article: FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer MoonshotGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the pharma industryGo to article: Key trends impacting ESG performance in the healthcare sectorGo to article: Latest news: ESG in pharmaGo to article: Sustainable supply chains: Clinical trials in a new era of limited resourcesGo to article: Increase in DPI use could lead to decreases in greenhouse gas emissionsGo to article: Environmental sustainability innovation: Leading companies in anti-malarial compositionsGo to article: Deal activity related to ESG in the pharmaceutical industry since 2020Go to article: ESG hiring trends in the global pharmaceutical industry since 2020Go to article: ESG patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of ESG in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: CfPIEGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue